The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis

Trends in Genetics

Volumn 29, Issue 3, 2013, Pages 160-169

  Müller, Borna ^a,b   Borrell, Sonia ^a,b   Rose, Graham ^c   Gagneux, Sebastien ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

Compensatory mutations; Drug resistance; Epistasis; Hypermutation; Persistence

Indexed keywords

AMIKACIN; CAPREOMYCIN; ETHAMBUTOL; ISONIAZID; KANAMYCIN; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; STREPTOMYCIN; VIOMYCIN;

BACTERIAL STRAIN; DRUG RESISTANT TUBERCULOSIS; DRUG TOLERANCE; EPISTASIS; ESCHERICHIA COLI; GENE MUTATION; HUMAN; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; SALMONELLA ENTERICA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIA; TREATMENT DURATION; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; BIOLOGICAL EVOLUTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EPISTASIS, GENETIC; GENETIC FITNESS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

BACTERIA (MICROORGANISMS); MYCOBACTERIUM TUBERCULOSIS;

EID: 84875264261     PISSN: 01689525     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tig.2012.11.005     Document Type: Review

References (90)

1. World Health Organization Global Tuberculosis Control: Surveillance, Planning, Financing 2012, World Health Organization.
2. Gandhi N.R., et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010, 375:1830-1843.
3. Caminero J.A., et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect. Dis. 2010, 10:621-629.
4. Velayati A.A., et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 2009, 136:420-425.
5. Udwadia Z.F., et al. Totally drug-resistant tuberculosis in India. Clin. Infect. Dis. 2012, 54:579-581.
6. Alanis A.J. Resistance to antibiotics: are we in the post-antibiotic era?. Arch. Med. Res. 2005, 36:697-705.
7. Zignol M., et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull. World Health Organ. 2012, 90:111D-119D.
8. Wells C.D., et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J. Infect. Dis. 2007, 196(Suppl. 1):S86-S107.
9. Dalton T., et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 2012, 380:1406-1417.
10. Kaplan G., et al. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect. Immun. 2003, 71:7099-7108.
11. Weiner M., et al. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob. Agents Chemother. 2007, 51:2861-2866.
12. Coscolla M., Gagneux S. Does M. tuberculosis genomic diversity explain disease diversity?. Drug Discov. Today Dis. Mech. 2010, 7:e43-e59.
13. Borrell S., Gagneux S. Strain diversity, epistasis and the evolution of drug resistance in Mycobacterium tuberculosis. Clin. Microbiol. Infect. 2011, 17:815-820.
14. Levin B.R., et al. The population genetics of antibiotic resistance. Clin. Infect. Dis. 1997, 24(Suppl. 1):S9-S16.
15. Keshavjee S., Farmer P.E. Tuberculosis, drug resistance, and the history of modern medicine. N. Engl. J. Med. 2012, 367:931-936.
16. Dye C., Espinal M.A. Will tuberculosis become resistant to all antibiotics?. Proc. R. Soc. Lond. B 2001, 268:45-52.
17. Dye C., et al. Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science 2002, 295:2042-2046.
18. Cohen T., Murray M. Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat. Med. 2004, 10:1117-1121.
19. Blower S.M., Chou T. Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance. Nat. Med. 2004, 10:1111-1116.
20. Borrell S., Gagneux S. Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 2009, 13:1456-1466.
21. Nguyen L., Pieters J. Mycobacterial subversion of chemotherapeutic reagents and host defense tactics: challenges in tuberculosis drug development. Annu. Rev. Pharmacol. Toxicol. 2009, 49:427-453.
22. Ramaswamy S., Musser J.M. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber. Lung Dis. 1998, 79:3-29.
23. Gagneux S., Small P.M. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect. Dis. 2007, 7:328-337.
24. Namouchi A., et al. After the bottleneck: genome-wide diversification of the Mycobacterium tuberculosis complex by mutation, recombination, and natural selection. Genome Res. 2012, 22:721-734.
25. Sandgren A., et al. Tuberculosis drug resistance mutation database. PLoS Med. 2009, 6:e2.
26. Luria S.E., Delbruck M. Mutations of bacteria from virus sensitivity to virus resistance. Genetics 1943, 28:491-511.
27. David H.L. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl. Microbiol. 1970, 20:810-814.
28. Gillespie S.H. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob. Agents Chemother. 2002, 46:267-274.
29. Post F.A., et al. Genetic polymorphism in Mycobacterium tuberculosis isolates from patients with chronic multidrug-resistant tuberculosis. J. Infect. Dis. 2004, 190:99-106.
30. Pasipanodya J.G., Gumbo T. A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs. Curr. Opin. Pharmacol. 2011, 11:457-463.
31. Perlman D.C., et al. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. Clin. Infect. Dis. 2005, 41:1638-1647.
32. Muller B., et al. InhA promoter mutations: a gateway to extensively drug-resistant tuberculosis in South Africa?. Int. J. Tuberc. Lung Dis. 2011, 15:344-351.
33. Louw G.E., et al. Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am. J. Respir. Crit. Care Med. 2011, 184:269-276.
34. Balaban N.Q. Persistence: mechanisms for triggering and enhancing phenotypic variability. Curr. Opin. Genet. Dev. 2011, 21:768-775.
35. Dhar N., McKinney J.D. Mycobacterium tuberculosis persistence mutants identified by screening in isoniazid-treated mice. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:12275-12280.
36. Adams K.N., et al. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell 2011, 145:39-53.
37. Balaban N.Q., et al. Bacterial persistence as a phenotypic switch. Science 2004, 305:1622-1625.
38. Aldridge B.B., et al. Asymmetry and aging of mycobacterial cells lead to variable growth and antibiotic susceptibility. Science 2012, 335:100-104.
39. Ford C.B., et al. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat. Genet. 2011, 43:482-486.
40. Jolivet-Gougeon A., et al. Bacterial hypermutation: clinical implications. J. Med. Microbiol. 2011, 60:563-573.
41. Rad M.E., et al. Mutations in putative mutator genes of Mycobacterium tuberculosis strains of the W-Beijing family. Emerg. Infect. Dis. 2003, 9:838-845.
42. Werngren J., Hoffner S.E. Drug-susceptible Mycobacterium tuberculosis Beijing genotype does not develop mutation-conferred resistance to rifampin at an elevated rate. J. Clin. Microbiol. 2003, 41:1520-1524.
43. de Steenwinkel J.E., et al. Drug susceptibility of Mycobacterium tuberculosis Beijing genotype and association with MDR TB. Emerg. Infect. Dis. 2012, 18:660-663.
44. Boshoff H.I., et al. DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis. Cell 2003, 113:183-193.
45. Ysern P., et al. Induction of SOS genes in Escherichia coli and mutagenesis in Salmonella typhimurium by fluoroquinolones. Mutagenesis 1990, 5:63-66.
46. Ren L., et al. Escherichia coli cells exposed to streptomycin display a mutator phenotype. J. Bacteriol. 1999, 181:1043-1044.
47. Takiff H., Guerrero E. Current prospects for the fluoroquinolones as first-line tuberculosis therapy. Antimicrob. Agents Chemother. 2011, 55:5421-5429.
48. Barnett M., et al. Tubercle bacilli resistant to isoniazid: virulence and response to treatment with isoniazid in guinea-pigs. Br. J. Exp. Pathol. 1953, 34:568-581.
49. Andersson D.I., Levin B.R. The biological cost of antibiotic resistance. Curr. Opin. Microbiol. 1999, 2:489-493.
50. Gagneux S., et al. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006, 312:1944-1946.
51. Billington O.J., et al. Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 1999, 43:1866-1869.
52. Davies A.P., et al. Comparison of fitness of two isolates of Mycobacterium tuberculosis, one of which had developed multi-drug resistance during the course of treatment. J. Infect. 2000, 41:184-187.
53. Pym A.S., et al. Effect of katG Mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infect. Immun. 2002, 70:4955-4960.
54. Sander P., et al. Fitness cost of chromosomal drug resistance-conferring mutations. Antimicrob. Agents Chemother. 2002, 46:1204-1211.
55. Bottger E.C., et al. Fitness of antibiotic-resistant microorganisms and compensatory mutations. Nat. Med. 1998, 4:1343-1344.
56. Gagneux S., et al. Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLoS Pathog. 2006, 2:e61.
57. van Doorn H.R., et al. Public health impact of isoniazid-resistant Mycobacterium tuberculosis strains with a mutation at amino-acid position 315 of katG: a decade of experience in The Netherlands. Clin. Microbiol. Infect. 2006, 12:769-775.
58. van Soolingen D., et al. Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands. J. Infect. Dis. 2000, 182:1788-1790.
59. Andersson D.I., Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance?. Nat. Rev. Microbiol. 2010, 8:260-271.
60. Levin B.R., et al. Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. Genetics 2000, 154:985-997.
61. Maisnier-Patin S., Andersson D.I. Adaptation to the deleterious effects of antimicrobial drug resistance mutations by compensatory evolution. Res. Microbiol. 2004, 155:360-369.
62. Hazbon M.H., et al. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2006, 50:2640-2649.
63. Sherman D.R., et al. Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 1996, 272:1641-1643.
64. Shcherbakov D., et al. Directed mutagenesis of Mycobacterium smegmatis 16S rRNA to reconstruct the in-vivo evolution of aminoglycoside resistance in Mycobacterium tuberculosis. Mol. Microbiol. 2010, 77:830-840.
65. Comas I., et al. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat. Genet. 2012, 44:106-110.
66. Casali N., et al. Microevolution of extensively drug-resistant tuberculosis in Russia. Genome Res. 2012, 22:735-745.
67. Brandis G., et al. Fitness-compensatory mutations in rifampicin-resistant RNA polymerase. Mol. Microbiol. 2012, 85:142-151.
68. Phillips P.C. Epistasis: the essential role of gene interactions in the structure and evolution of genetic systems. Nat. Rev. Genet. 2008, 9:855-867.
69. Ward H., et al. The cost of multiple drug resistance in Pseudomonas aeruginosa. J. Evol. Biol. 2009, 22:997-1003.
70. Hall A.R., MacLean R.C. Epistasis buffers the fitness effects of rifampicin-resistance mutations in Pseudomonas aeruginosa. Evolution 2011, 65:2370-2379.
71. Trindade S., et al. Positive epistasis drives the acquisition of multidrug resistance. PLoS Genet. 2009, 5:e1000578.
72. Rozen D.E., et al. Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 2007, 51:412-416.
73. Weinreich D.M., et al. Perspective: sign epistasis and genetic constraint on evolutionary trajectories. Evolution 2005, 59:1165-1174.
74. Salverda M.L., et al. Initial mutations direct alternative pathways of protein evolution. PLoS Genet. 2011, 7:e1001321.
75. Lieberman T.D., et al. Parallel bacterial evolution within multiple patients identifies candidate pathogenicity genes. Nat. Genet. 2011, 43:1275-1280.
76. Toprak E., et al. Evolutionary paths to antibiotic resistance under dynamically sustained drug selection. Nat. Genet. 2012, 44:101-105.
77. Bergval I., et al. Pre-existing isoniazid resistance, but not the genotype of Mycobacterium tuberculosis drives rifampicin resistance codon preference in vitro. PLoS ONE 2012, 7:e29108.
78. Elena S.F., Lenski R.E. Epistasis between new mutations and genetic background and a test of genetic canalization. Evolution 2001, 55:1746-1752.
79. Baker L., et al. Silent nucleotide polymorphisms and a phylogeny for Mycobacterium tuberculosis. Emerg. Infect. Dis. 2004, 10:1568-1577.
80. Fenner L., et al. Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2012, 56:3047-3053.
81. Comas I., et al. Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat. Genet. 2010, 42:498-503.
82. Niemann S., et al. Mycobacterium tuberculosis Beijing lineage favors the spread of multidrug-resistant tuberculosis in the Republic of Georgia. J. Clin. Microbiol. 2010, 48:3544-3550.
83. Chihota V.N., et al. Population structure of multi- and extensively drug-resistant Mycobacterium tuberculosis strains in South Africa. J. Clin. Microbiol. 2012, 50:995-1002.
84. Van Deun A., et al. Diagnosis of drug-resistant tuberculosis: reliability and rapidity of detection. Int. J. Tuberc. Lung Dis. 2010, 14:131-140.
85. Boehme C.C., et al. Rapid molecular detection of tuberculosis and rifampin resistance. N. Engl. J. Med. 2010, 363:1005-1015.
86. Zumla A., et al. Advancing the development of tuberculosis therapy. Nat. Rev. Drug Discov. 2012, 11:171-172.
87. McNerney R., et al. Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. J. Infect. Dis. 2012, 205(Suppl. 2):S147-S158.
88. Goldfeld A.E., et al. Association of an HLA-DQ allele with clinical tuberculosis. JAMA 1998, 279:226-228.
89. Comas I., Gagneux S. A role for systems epidemiology in tuberculosis research. Trends Microbiol. 2011, 19:492-500.
90. Gagneux S., et al. Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:2869-2873.